Firstly, we explored the inhibitory effect of COX-2/sEH dual inhibitor PTUPB (5 mg/kg, s.c. once a day) on HFD-induced NAFLD in mice (Figure 1A). Here, PTGS2 is linked to metabolic dysfunction-associated steatotic liver disease.